2 hours Immunovant (NASDAQ:IMVT) Stock Rating Reaffirmed by HC Wainwright MarketBeat
HC Wainwright reissued a “buy” rating and set a $51.00 price target on shares of Immunovant in a research report on Monday.
HC Wainwright reissued a “buy” rating and set a $51.00 price target on shares of Immunovant in a research report on Monday.